Hjalmar Flygt

Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry

Hjalmar Flygt, Fredrik Sandin, Torsten Dahlén et al. · British Journal of Haematology · 2021 · 15 citations · Full text

Medicine, Hematology, Pharmacotherapy +9

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study

Torsten Dahlén, Gustaf Edgren, Per Ljungman et al. · American Journal of Hematology · 2022 · 15 citations · Full text

Medicine, Oncology, Pharmacology +15

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

Hjalmar Flygt, Stina Söderlund, Johan Richter et al. · Leukemia · 2024 · 13 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Neurosurgical untethering with or without syrinx drainage results in high patient satisfaction and favorable clinical outcome in post-traumatic myelopathy patients

Ulrika Holmström, Parmenion P. Tsitsopoulos, Hjalmar Flygt et al. · Spinal Cord · 2018 · 11 citations

Medicine, Neurosurgery, Surgery +8

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study

Hjalmar Flygt, Stina Söderlund, Jesper Stentoft et al. · European Journal Of Haematology · 2021 · 10 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13